ALEMBIC PHARMA Latest Share Price (APLLTD)
TODAY IN ONE LINE
APLLTD slipped 0.7% on light volume, in line with Nifty's -0.3% move, supported by recent strong earnings.
With a market cap of ₹15,931.44 Cr., it trades at a P/E of 22.97. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ALEMBIC PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 29.2% YoY
- ●Steady Dividend YieldReliable 1.48% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.20x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 33.7% outpacing sales growth of 7.1%
Latest ALEMBIC PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
ALEMBIC PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ALEMBIC PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
ALEMBIC PHARMA trades at a P/E of 22.97× and P/B of 2.81×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ALEMBIC PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ALEMBIC PHARMA — derived from the latest tape, not yesterday's close.
ALEMBIC PHARMA last traded at ₹810.95 with an intraday range of ₹799.2–₹822 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹810.95| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 867.83 | +56.88 | +7.01% |
| R3 | 845.03 | +34.08 | +4.20% |
| R2 | 833.52 | +22.57 | +2.78% |
| R1 | 822.23 | +11.28 | +1.39% |
| PIVOT | 810.72 | -0.23 | -0.03% |
| CURRENT | 810.95 | — | — |
| S1 | 799.43 | -11.52 | -1.42% |
| S2 | 787.92 | -23.03 | -2.84% |
| S3 | 776.63 | -34.32 | -4.23% |
| S4 | 753.83 | -57.12 | -7.04% |
APLLTD is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹803.2–₹811.7
Trading Below opening range, showing Bearishness
ALEMBIC PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ALEMBIC PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
ALEMBIC PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,931.44 Cr. and reported EPS of ₹8.80.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 6,672 | 7,345 ▲ 10.1% |
| Sales Growth YoY %Derived | 7.12% | 10.08% |
| Other Income | 43 | 54 ▲ 27.9% |
| Total Income | 6,715 | 7,399 ▲ 10.2% |
| 1,793 | 1,984 ▲ 10.7% | |
| Gross ProfitDerived | 4,879 | 5,360 ▲ 9.9% |
| Gross Margin %Derived | 73.12% | 72.98% |
| 3,870 | 4,242 ▲ 9.6% | |
| EBITDA (Operating Profit)Derived | 1,008 | 1,118 ▲ 10.9% |
| OPM %Derived | 15.11% | 15.23% |
| 370 | 345 ▼ 6.8% | |
| Profit Before Tax (PBT) | 706 | 694 ▼ 1.8% |
| 125 | 23 ▼ 81.5% | |
| Effective Tax %Derived | 17.72% | 3.33% |
| Total Profit for Period | 582 | 671 ▲ 15.3% |
| Less: Non-controlling Interests | -1 | -4 ▼ 179.4% |
| Net Profit (Owner's PAT)Derived | 583 | 675 ▲ 15.7% |
| Net Profit Margin %Derived | 8.74% | 9.19% |
| PAT Growth YoY %Derived | -5.26% | 15.66% |
| Earnings Per Share (EPS ₹) | 29.68 | 34.33 ▲ 15.7% |
| Diluted Shares Outstanding (Cr) | 20 | 20 ▲ 0.0% |
| Share of Profit from Associates/JVs | 1 | 0 ▼ 72.4% |
| Other Comprehensive Income (Net of Tax) | 6 | 25 ▲ 349.7% |
| Total Expenses (incl. D&A & Interest) | 6,008 | 6,706 ▲ 11.6% |
| Material Cost % of RevenueDerived | 25.06% | 23.79% |
| Employee Cost % of RevenueDerived | 23.42% | 23.58% |
| Other Cost % of RevenueDerived | 34.59% | 34.17% |
| Interest Coverage (x)Derived | 9.26x | 8.54x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,131 | 3,935 ▲ 25.7% | 4,606 ▲ 17.1% | 5,393 ▲ 17.1% | 5,306 ▼ 1.6% | 5,653 ▲ 6.5% | 6,229 ▲ 10.2% | 6,672 ▲ 7.1% | 7,345 ▲ 10.1% | |
| Sales Growth YoY %Derived | — | 25.68% | 17.06% | 17.10% | -1.62% | 6.54% | 10.19% | 7.12% | 10.08% | |
| Other Income | 7 | 9 ▲ 33.4% | 5 ▼ 47.3% | 10 ▲ 102.7% | 50 ▲ 403.8% | 3 ▼ 94.6% | 28 ▲ 931.6% | 43 ▲ 50.3% | 54 ▲ 27.9% | |
| Total Income | 3,138 | 3,944 ▲ 25.7% | 4,611 ▲ 16.9% | 5,403 ▲ 17.2% | 5,356 ▼ 0.9% | 5,655 ▲ 5.6% | 6,257 ▲ 10.6% | 6,715 ▲ 7.3% | 7,399 ▲ 10.2% | |
886 | 993 ▲ 12.1% | 1,039 ▲ 4.7% | 1,257 ▲ 21.0% | 1,446 ▲ 15.0% | 1,709 ▲ 18.1% | 1,715 ▲ 0.4% | 1,793 ▲ 4.6% | 1,984 ▲ 10.7% | ||
| Gross ProfitDerived | 2,245 | 2,942 ▲ 31.0% | 3,566 ▲ 21.2% | 4,136 ▲ 16.0% | 3,859 ▼ 6.7% | 3,944 ▲ 2.2% | 4,514 ▲ 14.4% | 4,879 ▲ 8.1% | 5,360 ▲ 9.9% | |
| Gross Margin %Derived | 71.71% | 74.77% | 77.43% | 76.69% | 72.74% | 69.77% | 72.46% | 73.12% | 72.98% | |
1,602 | 2,068 ▲ 29.1% | 2,343 ▲ 13.3% | 2,578 ▲ 10.0% | 2,985 ▲ 15.8% | 3,235 ▲ 8.4% | 3,580 ▲ 10.7% | 3,870 ▲ 8.1% | 4,242 ▲ 9.6% | ||
| EBITDA (Operating Profit)Derived | 643 | 874 ▲ 35.8% | 1,223 ▲ 40.0% | 1,558 ▲ 27.4% | 874 ▼ 43.9% | 708 ▼ 19.0% | 933 ▲ 31.8% | 1,008 ▲ 8.0% | 1,118 ▲ 10.9% | |
| OPM %Derived | 20.54% | 22.20% | 26.55% | 28.88% | 16.48% | 12.53% | 14.98% | 15.11% | 15.23% | |
109 | 134 ▲ 22.8% | 141 ▲ 5.4% | 199 ▲ 41.7% | 305 ▲ 52.6% | 326 ▲ 6.9% | 329 ▲ 1.0% | 370 ▲ 12.6% | 345 ▼ 6.8% | ||
| Profit Before Tax (PBT) | 541 | 749 ▲ 38.4% | 1,000 ▲ 33.4% | 1,368 ▲ 36.8% | 620 ▼ 54.7% | 386 ▼ 37.8% | 633 ▲ 64.1% | 706 ▲ 11.6% | 694 ▼ 1.8% | |
120 | 157 ▲ 30.2% | 199 ▲ 27.1% | 253 ▲ 27.2% | 104 ▼ 58.8% | 13 ▼ 87.9% | 16 ▲ 27.0% | 125 ▲ 682.0% | 23 ▼ 81.5% | ||
| Effective Tax %Derived | 22.24% | 20.92% | 19.92% | 18.52% | 16.84% | 3.27% | 2.53% | 17.72% | 3.33% | |
| Total Profit for Period | 413 | 583 ▲ 41.3% | 801 ▲ 37.3% | 1,147 ▲ 43.2% | 521 ▼ 54.6% | 342 ▼ 34.4% | 616 ▲ 80.1% | 582 ▼ 5.5% | 671 ▲ 15.3% | |
| Less: Non-controlling Interests | 0 | 584 ▲ 299576.9% | -28 ▼ 104.8% | -32 ▼ 12.4% | -25 ▲ 21.7% | — ▲ 100.0% | — | -1 | -4 ▼ 179.4% | |
| Net Profit (Owner's PAT)Derived | 413 | -1 ▼ 100.3% | 829 ▲ 76842.5% | 1,178 ▲ 42.1% | 546 ▼ 53.7% | 342 ▼ 37.3% | 616 ▲ 80.1% | 583 ▼ 5.3% | 675 ▲ 15.7% | |
| Net Profit Margin %Derived | 13.18% | -0.03% | 18.00% | 21.84% | 10.28% | 6.05% | 9.89% | 8.74% | 9.19% | |
| PAT Growth YoY %Derived | — | -100.26% | 76,842.50% | 42.14% | -53.68% | -37.33% | 80.07% | -5.26% | 15.66% | |
| Earnings Per Share (EPS ₹) | 21.89 | -0.06 ▼ 100.3% | 43.97 ▲ 73383.3% | 59.94 ▲ 36.3% | 27.76 ▼ 53.7% | 17.40 ▼ 37.3% | 31.33 ▲ 80.1% | 29.68 ▼ 5.3% | 34.33 ▲ 15.7% | |
| Diluted Shares Outstanding (Cr) | 19 | 19 ▲ 0.0% | 19 ▲ 0.0% | 20 ▲ 4.3% | 20 ▲ 0.0% | 20 ▲ 0.0% | 20 ▲ 0.0% | 20 ▲ 0.0% | 20 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -8 | -9 ▼ 14.7% | 0 ▲ 100.6% | 32 ▲ 58677.8% | 5 ▼ 83.3% | -31 ▼ 685.0% | -1 ▲ 96.8% | 1 ▲ 188.9% | 0 ▼ 72.4% | |
| Other Comprehensive Income (Net of Tax) | -3 | 6 ▲ 282.5% | -2 ▼ 131.2% | -4 ▼ 102.8% | 1 ▲ 138.0% | 13 ▲ 854.0% | -11 ▼ 181.1% | 6 ▲ 151.0% | 25 ▲ 349.7% | |
| Total Expenses (incl. D&A & Interest) | 2,597 | 3,195 ▲ 23.0% | 3,611 ▲ 13.0% | 4,035 ▲ 11.7% | 4,736 ▲ 17.4% | 5,270 ▲ 11.3% | 5,624 ▲ 6.7% | 6,008 ▲ 6.8% | 6,706 ▲ 11.6% | |
| Material Cost % of RevenueDerived | 23.18% | 21.60% | 21.26% | 21.98% | 21.28% | 22.12% | 22.53% | 25.06% | 23.79% | |
| Employee Cost % of RevenueDerived | 19.89% | 18.98% | 19.68% | 19.49% | 21.35% | 20.68% | 23.22% | 23.42% | 23.58% | |
| Other Cost % of RevenueDerived | 31.28% | 33.59% | 31.20% | 28.31% | 34.91% | 36.56% | 34.26% | 34.59% | 34.17% | |
| Interest Coverage (x)Derived | 158.13x | 41.19x | 39.23x | 85.76x | 33.13x | 8.63x | 11.76x | 9.26x | 8.54x |
ALEMBIC PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at ALEMBIC PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
ALEMBIC PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ALEMBIC PHARMA.
Our AI distills the core fundamental drivers supporting ALEMBIC PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ALEMBIC PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Valuation risk. a P/E above 30 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ALEMBIC PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ALEMBIC PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ALEMBIC PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ALEMBIC PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ALEMBIC PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ALEMBIC PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ALEMBIC PHARMA stood at 41.4% of traded volume, against a 20-day average of 51.0%.
ALEMBIC PHARMA announcements: results, concalls, ratings, M&A.
Filings ALEMBIC PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ALEMBIC PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 240 documents below.
General Updates
Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited s Bioequivalence Facility in Vadodara, Gujarat
General Updates
Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and…
Analysts/Institutional Investor Meet/Con. Call Updates
Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Change in Company Secretary/Compliance Officer
Alembic Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer
Investor decks & rating reports.
ALEMBIC PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ALEMBIC PHARMA has declared, sequenced by announce and record date.
ALEMBIC PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
ALEMBIC PHARMA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in ALEMBIC PHARMA as reported to SEBI — buying and selling signals from the people who know the business best.
ALEMBIC PHARMA insider activity below tracks 11 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| NIRAYU LIMITED | Insider | 28 Mar 2025 | buy | +12.7 K | ₹1.15 Cr. | ₹905.13 |
| NIRAYU LIMITED | Insider | 21 Mar 2025 | buy | +7.6 K | ₹65.87 L | ₹866.74 |
| Chirayu Ramanbhai Amin HUF | Insider | 20 Mar 2025 | buy | +2.0 K | ₹16.69 L | ₹834.46 |
| Chirayu Ramanbhai Amin HUF | Insider | 18 Mar 2025 | buy | +1.5 K | ₹12.49 L | ₹832.52 |
| Chirayu Ramanbhai Amin HUF | Insider | 17 Mar 2025 | buy | +5.8 K | ₹48.19 L | ₹826.25 |
| Chirayu Ramanbhai Amin HUF | Insider | 27 Feb 2025 | buy | +50.0 K | ₹3.89 Cr. | ₹778.25 |
| Chirayu Ramanbhai Amin HUF | Insider | 25 Feb 2025 | buy | +7.4 K | ₹59.25 L | ₹797.91 |
| Chirayu Ramanbhai Amin HUF | Insider | 21 Feb 2025 | buy | +4.2 K | ₹34.24 L | ₹806.14 |
| Chirayu Ramanbhai Amin HUF | Insider | 20 Feb 2025 | buy | +959 | ₹7.79 L | ₹811.92 |
| Chirayu Ramanbhai Amin HUF | Insider | 14 Feb 2025 | buy | +10.0 K | ₹81.29 L | ₹812.90 |
About ALEMBIC PHARMA: business, sector, key facts.
What ALEMBIC PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ALEMBIC PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: APLLTD, BSE: 533573.
Alembic Pharmaceuticals Limited (APLLTD) is a fully integrated pharmaceutical company with a global reach. Its operations span the entire pharmaceutical value chain, from the initial research and development of new drugs to the final manufacturing, marketing, and sales of finished pharmaceutical products. This comprehensive approach allows them to exert greater control over quality and efficiency across all stages of production and distribution.
APLLTD's product portfolio is extensive and covers a wide range of therapeutic areas. This diversity is a key strength, allowing the company to cater to a broad spectrum of patient needs and market demands. Their offerings include products for cardiology, orthopaedics, diabetes management, ophthalmology, gynecology, nephrology, gastroenterology, urology, dermatology, infectious diseases, respiratory ailments (cold and cough), and even animal health. This diversification reduces reliance on any single therapeutic area and mitigates risk.
The company manufactures a variety of dosage forms, further showcasing its production capabilities. These include oral solid formulations (tablets and capsules), oncology-focused oral solids and injectables, general injectable medications, ophthalmic products, dermatological preparations, and oral suspensions. The production of active pharmaceutical ingredients (APIs) internally also grants APLLTD greater control over the supply chain and reduces dependence on external suppliers.
A significant aspect of APLLTD's business is its export operations. The company actively sells its products internationally, expanding its market reach and diversifying its revenue streams. This global presence provides resilience against fluctuations in any single national market and contributes significantly to the company's overall financial performance. The company's long history, dating back to 1907, demonstrates a sustained commitment to the pharmaceutical industry and suggests a strong foundation of experience and expertise.
In summary, Alembic Pharmaceuticals Limited operates as a comprehensive pharmaceutical company, engaged in the entire life cycle of pharmaceutical products, from research to global distribution. Its diversified product portfolio, wide range of dosage forms, and international reach contribute to its established position within the pharmaceutical market. The company's long history and vertical integration provide a solid base for continued growth and success.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ALEMBIC PHARMA (APLLTD).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ALEMBIC PHARMA (APLLTD)?
The current share price of ALEMBIC PHARMA (APLLTD) is ₹810.95. Today, the stock has declined by ₹5.45 (0.67%), trading in a range of ₹799.20 to ₹822.00. The stock opened at ₹806.00 with a trading volume of 1,18,504 shares.
02Is ALEMBIC PHARMA stock a good investment for long-term?
ALEMBIC PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,931.44 Cr., P/E ratio of 22.97, ROE of 11.4%, and ROCE of 10.99%. The dividend yield stands at 1.48%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ALEMBIC PHARMA stock?
The 52-week high price of ALEMBIC PHARMA (APLLTD) is ₹998.00, while the 52-week low is ₹635.80. Currently trading at ₹810.95, the stock is 27.55% above its 52-week low and 18.74% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ALEMBIC PHARMA stock at the current price?
Whether to buy ALEMBIC PHARMA stock at ₹810.95 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.97 and P/B ratio of 2.81. Today's performance shows a loss of 0.67%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ALEMBIC PHARMA and when is the next dividend?
ALEMBIC PHARMA offers a dividend yield of 1.48%, which means for every ₹100 invested at the current price of ₹810.95, you can expect to receive approximately ₹1.48 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ALEMBIC PHARMA?
ALEMBIC PHARMA's key financial metrics include: P/E Ratio: 22.97, P/B Ratio: 2.81, ROE: 11.4%, ROCE: 10.99%, Dividend Yield: 1.48%, EPS: ₹8.80, Book Value: ₹288.41, and Debt-to-Equity: 0.2. The company's market cap stands at ₹15,931.44 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ALEMBIC PHARMA stock performing today in the market?
ALEMBIC PHARMA stock opened at ₹806.00 and is currently trading at ₹810.95, showing a decline of ₹5.45 (0.67%). The intraday high is ₹822.00 and low is ₹799.20. The trading volume stands at 1,18,504 shares, indicating moderate market participation today.
08What is the P/E ratio of ALEMBIC PHARMA and what does it indicate?
ALEMBIC PHARMA has a Price-to-Earnings (P/E) ratio of 22.97, which means investors are willing to pay 22.97 for every ₹1 of earnings. With an EPS of ₹8.80, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ALEMBIC PHARMA (APLLTD) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.